Log in

NASDAQ:SEELSeelos Therapeutics Stock Price, Forecast & News

-0.03 (-2.38 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $1.23
50-Day Range
MA: $0.71
52-Week Range
Now: $1.23
Volume884,906 shs
Average Volume2.10 million shs
Market Capitalization$55.29 million
P/E RatioN/A
Dividend YieldN/A
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SEEL



Sales & Book Value

Annual Sales$380,000.00
Book Value$0.15 per share


Net Income$-51,260,000.00


Market Cap$55.29 million
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

How has Seelos Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SEEL shares have increased by 57.7% and is now trading at $1.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Seelos Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seelos Therapeutics.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Seelos Therapeutics.

How were Seelos Therapeutics' earnings last quarter?

Seelos Therapeutics Inc (NASDAQ:SEEL) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.08. View Seelos Therapeutics' earnings history.

What price target have analysts set for SEEL?

3 Wall Street analysts have issued twelve-month target prices for Seelos Therapeutics' shares. Their forecasts range from $4.00 to $8.00. On average, they expect Seelos Therapeutics' share price to reach $5.33 in the next twelve months. This suggests a possible upside of 333.6% from the stock's current price. View analysts' price targets for Seelos Therapeutics.

Has Seelos Therapeutics been receiving favorable news coverage?

Media headlines about SEEL stock have been trending positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Seelos Therapeutics earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutSeelos Therapeutics.

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:
  • Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.13%), BlackRock Inc. (1.17%) and 1492 Capital Management LLC (0.33%). View institutional ownership trends for Seelos Therapeutics.

Which major investors are buying Seelos Therapeutics stock?

SEEL stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, 1492 Capital Management LLC, and BlackRock Inc.. View insider buying and selling activity for Seelos Therapeutics.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $1.23.

How big of a company is Seelos Therapeutics?

Seelos Therapeutics has a market capitalization of $55.29 million and generates $380,000.00 in revenue each year.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-293-2100 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.